versão impressa ISSN 0074-0276
versão On-line ISSN 1678-8060
Mem. Inst. Oswaldo Cruz v.99 n.7 Rio de Janeiro nov. 2004
Nadja MF LimaI; Clariane S CorreiaI; Leonor L LeonII; Gérzia MC MachadoII; Maria de Fátima MadeiraII; Antônio Euzébio G SantanaI; Marília OF GoulartI, 1
IDepartamento de Química, CCEN, Universidade Federal de Alagoas, Tabuleiro do Martins, 57072-970 Maceió, AL, Brasil
IIDepartamento de Imunologia, Instituto Oswaldo Cruz-Fiocruz, Rio de Janeiro, RJ, Brasil
The antileishmanial activity of lapachol, isolapachol, and dihydrolapachol, along with soluble derivatives (potassium salt) and acetate was obtained. All the compounds were assayed against metacyclic promastigotes of two different species of Leishmania associated to tegumentar leishmaniasis: L. amazonensis and L. braziliensis. All compounds presented significant activity, being isolapachol acetate the most active against promastigotes, with IC50/24h = 1.6 ± 0.0 µg/ml and 3.4 ± 0.5 µg/ml for, respectively, L. amazonensis and L. braziliensis. This compound was also assayed in vivo against L. amazonensis and showed to be active. Its toxicity in vitro was also established, and at concentration similar to the IC50, no toxicity was evidenced. In all experiments, pentamidine isethionate was used as a reference drug. The present results reinforce the potential use of substituted hydroxyquinones and derivatives as promising antileishmanial drugs and suggest a continuing study within this class of compounds.
Key words: Leishmania amazonensis - Leishmania braziliensis - lapachol - isolapachol - antileishmanial activity - naphthoquinones
Leishmaniasis is one of the major infectious diseases affecting the poorest regions of the world. Human infections with Leishmania protozoan parasites, transmitted by the bite of a sand fly, cause visceral, cutaneous or mucocutaneous leishmaniasis (Davies et al. 2003). Leishmania/HIV co-infections, as well as classic forms of leishmaniasis still impose difficulties in terms of diagnosis and treatment. The global burden of leishmaniasis has remained stable for some years, causing 2.4 million disability adjusted life years lost and 59000 deaths in 2001 (WHO 2002). Drug treatment today, besides the pentavalent antimonials, is restricted to a limited number of drugs like pentamidine isethionate, amphotericin B, and miltefosine (Davies et al. 2003, Kayser et al. 2003). All those drug therapies cause serious side effects. Furthermore, general treatment is unaffordable for many afflicted countries revealing an urgent need for new, safer, and cheaper drugs (Kayser et al. 2003).
One strategy to discover new therapeutic leads is to investigate classes of compounds potentially bioactive or old active compounds for alternative uses. Quinones, in general, and, particularly hydroxyquinones, as well as their reduced derivatives, have been tested against several parasite species (Croft et al. 1992, Sauvain et al. 1993, Iwu et al. 1994, Ray et al. 1998, Kayser et al. 2000, Pinto et al. 2000, Ferreira et al. 2002, Hazra et al. 2002). Many naphthoquinones have been identified as possible lead structures against Leishmania and other protozoa, but the potential usefulness is limited by their cytotoxicity and low bioavailability (Kayser et al. 2000). Atovaquone, a hydroxynaphtoquinone, showed to have a concentration-dependent in vitro activity against L. infantum (Jernigan et al. 1996), while the in vivo activity in a murine model remained low (Murray et al. 1996, Cauchetier et al. 2000). Lapachol was effective in vitro against intracellular amastigotes of L. braziliensis, whereas in a hamster model, it was unable to prevent lesions induced by the infection (Teixeira et al. 2001). It was suggested that lapachol could be transformed in vivo into an inactive metabolite (Teixeira et al. 2001). Apart from these studies, lapachol and other quinones are known to possess antitumor, antibiotic, antimalarial, anti-inflammatory, and anti-ulcer activities (Subramanian et al. 1998, reviewed in De Moura et al. 2001). Recent results showed that lapachol, isolapachol and its acetylderivative possess significant activity against Biomphalaria glabrata, the intermediate host of Schistosoma mansoni (Goulart et al. 1997, dos Santos et al. 2000, 2001, Lima et al. 2002). Their mechanism of biological action is still uncertain, despite some reported studies. Lapachol was shown to be a vitamin K antagonist, and, thus, might target vitamin K-dependent reactions (Dinnen & Ebisuzaki 1997) and also to be bioactivated by P450 reductase to reactive species, which promote DNA scission through redox cycling with generation of free radicals (Kumagai et al. 1997). The involvement of reactive oxygen species in the mechanism of action of lapachol and isolapachol was suggested by electrochemical studies in the presence of oxygen (Goulart et al. 2003, 2004). Di-hydrolapachol was active against Plasmodium lophurae in ducks (Hooker & Richardson 1948).
The aim of the present study was to conduct an evaluation of the activity of lapachol and analogues 1-6 (Fig. 1) against two species of Leishmania from the New World.
Fig. 1: compounds submitted to the leishmanicidal assays.
MATERIALS AND METHODS
Compounds - Lapachol (1) is from natural origin, extracted from the heartwood of several plants of the bignoniaceae family, mainly from Tecoma and Tabebuia species (Thomson 1971) and kindly supplied by Produtos Vegetais do Piauí, Parnaíba, Piauí, Brazil. Isolapachol [2-hydroxy-3-(3-methyl-1-butenyl)-1,4-naphthoquinone] (2) was easily synthesized, following established procedures, by reaction of 2-hydroxy-1,4-naphthoquinone (Sigma-Aldrich, Steinheim, Germany) and isovaleraldehyde (Sigma-Aldrich), in acidic medium (Hooker 1936b). Lapachol and isolapachol salts (3 and 4, respectively) were prepared by the use of an equivalent amount of KOH in ethanol, distillation of the solvent and several washings with cold ether to eliminate residues of the initial compounds. Acetylisolapachol (2-acetoxy-3-(3-methyl-1-butenyl)-1,4-naphthoquinone) (5) was prepared from 2 g of isolapachol (2) (8.2 mmol) by reaction with anhydrous sodium acetate (2 g, 3.95 mmol) and acetic anhydride (13 ml, 10,58 mmol), with stirring, under reflux during 30 min. Work up consisted in water addition and filtration of the precipitate (Hooker 1896). The dihydrolapachol (2-hydroxy-3-(3-methylbutyl)-1,4-naphthoquinone) (6) preparation involved catalytic hydrogenation of lapachol (1) (0.295 g, 1.22 mmol), using PtO2 on charcoal (10%) in ethanol, separation of the catalyst by filtration and distillation of the solvent (Hooker 1936a). All the compounds presented analytical and spectral (IR, NMR) data in full agreement with the structures shown in Fig. 1.
Culture media, parasites, assays - L. amazonensis (MHOM/BR/77/LTB0016 strain) promastigotes were grown at 26°C in Schneider's Drosophila medium supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS), pH 7.2. L. braziliensis (MCAN/BR/98/R619) promastigotes were grown in the same medium, same temperature and pH, but supplemented with 20% FCS and 2% human urine (Howard et al. 1991, Shamsuzzaman et al. 1999). Parasites were harvested from the medium on day 4, when a high percentage of infective forms (metacyclic promastigotes) was found. After being harvested, the parasites were counted in Neubauer's chamber and adjusted to a concentration of 4x106 promastigotes/ml using the supernatant of each culture as diluent.
Drugs were dissolved in DMSO (the highest concentration was 1.4%, which was not hazardous to the parasites) (Canto-Cavalheiro et al. 1997) and added to parasites suspensions in a final concentration between 0.156 µg/ml and 320 µg/ml. After 24 h of incubation, the parasites were counted and compared to the controls, containing DMSO and parasites alone. Pentamidine isethionate was used as a reference drug. The drug concentration corresponding to 50% of parasite growth inhibition was expressed as the IC50.
Toxicity of compound 5 to mammalian cells - Peritoneal macrophages were collected from outbread mice, counted in a Neubauer chamber, adjusted to a concentration of 1-2 x106 cells/ml and plated in the Lad-Tek chamber (no. 154534 Nalge Nunc International, Naperville, IL 60563, US). Macrophages were incubated for 2-3 h at 37°C under CO2 atmosphere with further washing with pre-heated RPMI, to remove the non-adherent cells. After washing, RPMI containing 100 U penicillin, 50 mg/ml streptomycin and 10% FCS, was added and the cells were incubated for 24 h at 37°C. Compound 5 was added to the cultures in two concentrations, 1.6 µg/ml and 3.2 µg/ml, which correspond to 1X and 2X the IC50/24h, obtained from the assay with L. amazonensis promastigotes. The incubation was performed for 24 and 48 h in the same conditions described above. The slides were washed with PBS, fixed with methanol, dried, stained with Trypan blue and/or Giemsa and analyzed using an optical microscope (Pinho et al. 1981).
In vivo activity of compound 5 - Swiss mice were divided in four groups: a) non-infected mice (NInf); infected mice (Inf) injected subcutaneously (s.c.) in the footpad with 1x107 of infective promastigotes in 50 µl culture medium; infected and treated mice (T1) injected s.c. with 5 at the dose of 1XIC50 (1.6 µg/ml/animal) at 1 day post-infection (dpi) and 7 dpi; infected and treated mice (T2) injected s.c. with 5 at the dose of 2XIC50 (3.2 µg/ml/animal) at 1 dpi and 8 dpi (culture medium, saline, whatever was used to resuspend the parasites). All groups were analyzed during seven weeks according to the footpad size.
RESULTS AND DISCUSSION
In this report, we evaluated the effect of 1 to 6 against two different species of Leishmania from the New World: L. amazonensis which has been associated with all clinical forms of leishmaniasis (Barral et al. 1991, Leon et al. 1992), and L. braziliensis that usually presents high invasive capacity resulting in deforming mucocutaneous manifestations, and is endemic in the state of Rio de Janeiro, Brazil.
In general, the compounds showed activity against promastigote forms in the range of IC50/24h 1.6 to 7.8 µg/ml for L. amazonensis and 3.4 to 54.0 µg/ml for L. braziliensis (Table). The differences in their activities against both parasites could be associated to the culture conditions, since L. braziliensis promastigotes were cultivated with a high amount of fetal calf serum. This fact would result in a lower availability of the compound, since some serum protein or protein from urine could aggregate with the assayed drug, which has already been described (Da Silva et al. 2002). Besides, considering that both parasites have their own metabolic characteristics, it would be expected a difference in the activity of different compounds, which probably would be metabolized in different ways. Furthermore, it was previously observed that a particular parasite (Trypanosoma evansi) isolated from several sources, presented a significant difference concerning the resistance to the same drug (Gomes-Cardoso et al. 1999). Our data showed that among the lapachol analogues assayed against L. amazonensis and L. braziliensis, the most effective was the acetylisolapachol (5), being the highest activity observed against L. amazonensis (IC50/24h = 1.6 ± 0.0 µg/ml) (Table). As expected, pentamidine isethio-nate, the reference drug, was the most active against L. amazonensis (IC50/24h = 0.28 ± 0.05 µg/ml). However, previous data from our laboratory showed that pentamidine isethionate is highly toxic, in vitro, against peritoneal ma-crophage of mice as well as in vivo (Temporal et al. 2002).
The most active derivative in vitro, compound 5, was chosen for additional assays. When macrophages were incubated with the compound, during 24 and 48 h, in a concentration equivalent to IC50/24 h (1.6 µg/ml), the morphology observed was similar to those of the control group. However, when the concentration was 3.2 µg/ml, only 20% of the cells were preserved during 24 h incubation. With 48 h incubation, compound 5 was injected into outbread mice in two different concentrations, such as, the equivalent to IC50 from the in vitro experiment and twice this value. No difference was observed comparing treated/non-treated groups of mice in both concentrations, up to 4th week, after parasite injection. However, from the 5th week, an increase in the effect of the compound 5 in both concentrations used can be seen, with a decrease in the footpad size (Fig. 2).
Fig. 2: in vivo activity of acetylisolapachol 5 in Ninf, Inf, T1, and T2 groups, during seven days post-infection. From the 5th week, a decrease in the footpad size in T1 and T2 can be observed.
Concerning the toxicity of hydroxyquinones, important for further in vivo studies, no systematic study had been undertaken, even though such information would be valuable in view of the potential and therapeutic use of such substrates (Munday et al. 1995). Concerning lapachol, its toxicology was studied extensively (Duke 2002). In an early study, it showed to be a hemolytic agent in dogs and monkeys although renal histology was reported to be normal in both species (Morrison et al. 1970). Hemolytic anemia was found to be the limiting toxicity in animal studies (Duke 2002). It has also shown strong interceptive effect in rats with 100% fetal/embryo mortality, without affecting the mothers (Guerra et al. 1999). Human toxicity was verified at dose greater than 1.5 g per day (Duke 2002). For isolapachol, no data, except those from our group (Lima et al. 2002), had been hitherto reported.
Our results are promising since this hydroxyquinone derivative 5 showed to be active both in vitro and in vivo against L. amazonensis and in vitro against L. braziliensis. Furthermore, the in vitro experiment with macrophage demonstrated that in a concentration equivalent to IC50, this compound is not hazardous to the host cell, fact that suggests a continuing study within this class of compounds toward in vivo assays. The present results reinforce the potential use of substituted hydroxyquinones and derivatives as very promising antileishmanial drugs.
To Produtos Vegetais do Piauí, Parnaíba, Piauí, Brazil for the kind gift of lapachol.
Barral A, Pedral-Sampaio D, Grimaldi Jr G, Momen H, Mc-Mahon-Pratt D, Ribeiro de Jesus A, Almeida R, Badaró R, Barral-Neto M, Carvalho EM, Johnson Jr WD 1991. Leishmaniasis in Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am J Trop Med Hyg 44: 536-546. [ Links ]
Canto-Cavalheiro MM, Echevarria A, Araújo CA, Bravo MF, Santos LHS, Jansen A M, Leon LL 1997. The potential effects of new synthetic drugs against Leishmania amazonensis and Trypanosoma cruzi. Microbios 90: 51-60. [ Links ]
Cauchetier E, Loiseau PM, Lehman J, Rivollet D, Fleury J, Astier A, Deniau M, Paul M 2002. Characterization of atovaquone resistance in Leishmania infantum promasti-gotes. Int J Parasitol 32: 1043-1051. [ Links ]
Croft SL, Hogg J, Gutteridge WE, Hudson AT, Randall AW 1992. The activity of hydroxynaphthoquinones against Leishmania donovani. J Antimicrob Chemother 30: 827-832. [ Links ]
Da Silva ED, Canto-Cavalheiro MM, Braz VR, Cysne-Finkelstein L, Leon LL, Echevarria A. 2002. Synthesis and biological evaluation of a new 1,3,4-thiadiazolium-2-phenylamine derivatives against Leishmania amazonensis promastiogtes and amastigotas. Eur J Med Chem 37: 979-984 [ Links ]
Davies CR, Kaye P, Croft SL, Sundar S 2003. Leishmaniasis: new approaches to disease control. Brit Med J 326: 377-382. [ Links ]
De Moura KCG, Emery FS, Neves-Pinto C, Pinto MCFR, Dantas AP, Salomão K, De Castro SL, Pinto AV 2001. Synthesis and trypanocidal activity of naphthoquinones isolated from Tabebuia and heterocyclic derivatives. A review from an interdisciplinary study. J Braz Chem Soc 12: 325-338. [ Links ]
Dinnen RD, Ebisuzaki K 1997. The search for novel anticancer agents: a differentiation-based assay and analysis of a folklore product. Anticancer Res 17: 1027-1033. [ Links ]
Dos Santos AF, Ferraz PAL, De Abreu FC, Chiari E, Goulart MOF, Sant'Ana AEG 2001. Molluscicidal and trypanocidal activities of lapachol derivatives. Planta Med 67: 92-93. [ Links ]
Dos Santos AF, Ferraz PAL, Pinto AV, Pinto MCRF, Goulart MOF, Sant'Ana AEG 2000. Molluscicidal activity of 2-hydroxy-3-alkyl-1,4-naphthoquinones and derivatives. Int J Parasitol 30: 1199-1202. [ Links ]
Duke J A 2002. Handbook of Medicinal Herbs, 2nd ed., CRC Press, Boca Raton, FL. [ Links ]
Ferreira RA, Oliveira ABM, Gualberto SA, Vitor RW 2002. Activity of natural and synthetic naphthoquinones against Toxoplasma gondii in vitro and in murine models of infection. Parasite 9: 261-269. [ Links ]
Gomes-Cardoso L, Echevarria A, Aguiar-Alves F, Jansen AM, Leon LL1999. Amidine derivatives are highly effective against Trypanosoma evansi trypomastigotes. Microbios 100: 181-187 [ Links ]
Goulart MOF, Zani CL, Tonholo J, De Abreu FC, Raslan DS, Starling S, Oliveira AB, Chiari E 1997. Trypanocidal activity and redox potentials of heterocyclic and 2-hydroxy-naphthoquinones. Bioorg Med Chem Lett 7: 2043-2048. [ Links ]
Goulart MOF, Liwo A, Falkowsky P, Ossowsky T 2003. Electrochemical study of oxygen interaction with lapachol and its radical anions. Bioelectrochem 59: 85-87. [ Links ]
Goulart MOF, Lima NMF, Sant'Ana AEG, Ferraz PAL, Ca-valcanti JCM, Liwo A, Falkowsky P, Ossowsky T 2004. Electrochemical studies of isolapachol with emphasis on oxygen interaction with its radical anions. J Electroanal Chem 566: 25-29. [ Links ]
Guerra MO, Mazoni ASB, Brandão MAF, Peters VM 1999. Interceptive effect of Lapachol in rats. Contraception 60: 305-307. [ Links ]
Hazra B, Sarkar R, Bhattacharyya S, Ghosh PK, Chel G, Dinda B 2002. Synthesis of plumbagin derivatives and their inhibitory activities against Ehrlich ascites carcinoma in vivo and Leishmania donovani promastigotes in vitro. Phytother Res 16: 133-137. [ Links ]
Hooker SC 1936a. Lomatiol. Part II. Its occurrence, constitution, relation to and conversion into lapachol. Also a synthesis of lapachol. J Am Chem Soc 59: 1181-1190. [ Links ]
Hooker SC 1936b. The constitution of lapachol and its derivatives. The structure of Paterno's isolapachol. J Am Chem Soc 59: 1190-1195. [ Links ]
Hooker SC, Richardson AP 1948. Naphthoquinone antimala-rials. II. Correlation of structure and activity against P. lophurae in ducks. J Am Chem Soc 70: 3156-3165. [ Links ]
Howard MK, Pharoah MM, Ashall F, Miles MA 1991. Human urine stimulates growth of Leishmania in vitro. Trans R Soc Trop Med Hyg 85: 477-479. [ Links ]
Iwu MM, Jackson JE, Schuster BG.1994. Medicinal plants in the fight against leishmaniasis. Parasitol Today 10: 65-68. [ Links ]
Jernigan JA, Pearson RD, Petri WA, Rogers MD 1996. In vitro activity of atovaquone against Leishmania chagasi promastigotes. Antimicrob Agents Chemother 40: 1064-1064. [ Links ]
Kayser O, Kiderlen AF, Croft SL 2003. Antileshmanial activity of two g-pyrones from Podolepsis hieracioides (Asteraceae). Acta Trop 86: 105-107. [ Links ]
Kayser O, Kiderlen AF, Laatsch H, Croft SL 2000. In vitro leishmanicidal activity of monomeric and dimeric naphthoquinones. Acta Trop 77: 307-314. [ Links ]
Kumagai Y, Tsurutani Y, Shinyashiki M, Takeda SH, Nakai Y, Yoskikawa T, Shimojo N 1997. Bioactivation of lapachol responsible for DNA scission by NADPH-cytochrome P450 reductase. Environm Toxicol Pharmacol 3: 245-250. [ Links ]
Leon LL, Machado GMC, Barral A, Carvalho-Paes LE, Grimaldi Jr G 1992. Antigenic differences among Leishmania amazonensis isolates and their relationship with distinct clinical forms of the disease. Mem Inst Oswaldo Cruz 87: 229-234. [ Links ]
Lima NMF, Dos Santos AF, Porfírio Z, Goulart MOF, Sant'ana AEG 2002. Toxicity of lapachol and isolapachol and their potassium salts against Biomphalaria glabrata, Schistosoma mansoni cercariae, Artemia salina and Tilapia nilotica. Acta Trop 83: 43-47. [ Links ]
Morrison RK, Brown DE, Oleson JJ, Cooney DA 1970. Oral toxicology studies with lapachol. Toxicol Appl Pharmacol 17: 1-5. [ Links ]
Munday R, Smith BL, Munday CM 1995. Comparative toxicity of 2-hydroxy-3-alkyl-1,4-naphthoquinones in rats. Chemico-Biol Interact 98: 185-192. [ Links ]
Murray HW, Hariprashad J 1996. Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis. Antimicrobial Agents Chemother 40: 586-587. [ Links ]
Pinho RT, Kloetzel JK, Milder RV 1981. Macrophage - Trypanosome infection, dead and live cell scoring. Rev Inst Med Trop São Paulo 23: 96. [ Links ]
Pinto CN, Dantas ASP, De Moura KC, Emery FS, Polequevitch PF, Pinto MC, De Castro SL, Pinto AV 2000. Chemical reactivity studies with naphthoquinones from Tabebuia with anti-trypanosomal efficacy. Arzneim Forsch/Drug Res 50: 1120-1128. [ Links ]
Ray S, Hazra B, Mittra B, Das A, Majumder HK 1998. Diospyrin, a bisnaphthoquinone: a novel inhibitor of type I DNA topoisomerase of Leishmania donovani. Mol Pharmacol 54: 994-999. [ Links ]
Sauvain M, Dedet JP, Kunesch N, Poisson J, Gantier JC, Gairal P, Kunesch G 1993. In vitro and in vivo leishmanicidal activities of natural and synthetic quinoids. Phytotherap Res 7: 167-171. [ Links ]
Shamsuzzaman SM, Furuya M, Korenaga M, Imamura K, Hashiguchi Y 1999. Use of urine samples from healthy humans, nephritis patients or other animals as an alternative to foetal calf serum in the culture of Leishmania (L.) donovani in vitro. Ann Trop Med Parasitol 93: 613-620. [ Links ]
Subramanian S, Ferreira MMC, Trsic M 1998. Structure-activity relationship study of lapachol and some derivatives of 1,4-naphthoquinones against carcinosarcoma Walker 256. Struct Chem 9: 47-57. [ Links ]
Teixeira MJ, De Almeida YM, Viana JR, Holanda JG, Rodrigues TP, Prata JRC, Coelho IVB, Rao VS, Pompeu MML 2001. In vitro and in vivo leishmanicidal activity of 2-hydroxy-3- (3-methyl-2-butenyl)-1,4-naphthoquinone (lapachol). Phytother Res 15: 44-48. [ Links ]
Temporal RM, Cysne-Finkelstein L, Echevarria A, Sousa MAS, Sertã M, Silva-Gonçalves A, Pirmez C, Leon LL 2002. Effects of amidine derivatives on parasite-macrophage interaction and evaluation of toxicity. Arzneim Forsch/Drug Res 6: 489-493. [ Links ]
Thomson RH 1971. In Naturally Occurring Quinones, Academic Press, New York, 203 pp. [ Links ]
WHO-World Health Organization 2002. Annex 3: Burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2001. The World Health Report. Geneva. [ Links ]
Received 27 April 2004
Accepted 20 September 2004
Financial support: CNPq, RHAE/CNPq, Capes, Fapeal, Papes/PDTIS/Fiocruz